Jardiance vs. Farxiga
See how Jardiance and Farxiga compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Jardiance and Farxiga are both once-daily SGLT2 inhibitors approved for type 2 diabetes, heart failure, and chronic kidney disease, with largely overlapping benefits.
Jardiance's label lists a notably higher hypoglycemia rate when combined with insulin or sulfonylureas, while Farxiga's label sets a specific eGFR cutoff for glycemic use.
Neither drug is approved for type 1 diabetes or diabetic ketoacidosis treatment, and both carry warnings for genital infections, volume depletion, and ketoacidosis risk.
Jardiance vs. Farxiga Drug Summary
Jardiance
Jardiance (empagliflozin) is an SGLT2 inhibitor used to manage blood sugar in type 2 diabetes and to reduce cardiovascular and kidney risks in adults with related heart or kidney disease. It comes as an oral tablet taken once daily, usually starting at 10 mg.
Farxiga
Farxiga (dapagliflozin) is also an SGLT2 inhibitor, prescribed for blood sugar control in type 2 diabetes as well as for heart failure and chronic kidney disease. It is an oral tablet taken once daily, typically starting at 5 mg.
Jardiance vs. Farxiga Side Effects
Jardiance
Farxiga
Jardiance vs. Farxiga Dosage
Jardiance
Farxiga
| STAGE | DOSE | WHEN |
| Starting dose | 10 mg once daily | At the start |
| Maximum dose | 25 mg once daily | If needed |
| Dose changes | 1 increase | As tolerated |
| STAGE | DOSE | WHEN |
| Starting dose | 5 mg once daily | At the start |
| Maximum dose | 10 mg once daily | If needed |
| Dose changes | 1 increase | As tolerated |
Jardiance
| STAGE | DOSE | WHEN |
| Starting dose | 10 mg once daily | At the start |
| Maximum dose | 25 mg once daily | If needed |
| Dose changes | 1 increase | As tolerated |
Farxiga
| STAGE | DOSE | WHEN |
| Starting dose | 5 mg once daily | At the start |
| Maximum dose | 10 mg once daily | If needed |
| Dose changes | 1 increase | As tolerated |
Jardiance vs. Farxiga Indications
Jardiance
Jardiance is approved to lower blood sugar in type 2 diabetes, reduce cardiovascular death in people with type 2 diabetes and heart disease, and treat heart failure regardless of ejection fraction. It is also approved to slow chronic kidney disease progression and lower the risk of kidney failure, cardiovascular death, and related hospitalization.
Blood sugar control in adults and children 10+ with type 2 diabetes
Reduce cardiovascular death in type 2 diabetes with heart disease
Reduce death and hospitalization in heart failure, any ejection fraction
Slow chronic kidney disease progression and reduce related hospitalization
Farxiga
Farxiga is approved to lower blood sugar in type 2 diabetes, reduce heart failure hospitalization in people with type 2 diabetes and cardiovascular risk factors, and treat heart failure across both reduced and preserved ejection fraction. It is also approved to slow chronic kidney disease progression and lower the risk of kidney failure and cardiovascular death.
Blood sugar control in adults and children 10+ with type 2 diabetes
Reduce heart failure hospitalization risk in type 2 diabetes
Treat heart failure across reduced and preserved ejection fraction
Slow chronic kidney disease progression and reduce kidney failure risk
Jardiance vs. Farxiga Pros and Cons
Jardiance
Jardiance's label highlights a specific cardiovascular death indication for people with established heart disease and does not spell out an eGFR floor or dialysis contraindication for glycemic use. It also reports a notably high hypoglycemia rate when combined with insulin or sulfonylureas, along with higher rates of volume depletion and urinary tract infection than Farxiga's label shows.
Pros
FDA-approved specifically to reduce cardiovascular death in type 2 diabetes with existing heart disease
No labeled eGFR cutoff stated for glycemic use, unlike Farxiga's 45 mL/min/1.73m2 floor
No labeled dialysis contraindication, unlike Farxiga
Cons
Hypoglycemia risk can reach up to 41.3% when combined with insulin or sulfonylureas
Volume depletion reactions reported in up to 11.4% of patients
Higher urinary tract infection rate (up to 9.3%) than Farxiga's (up to 4.3%)
Farxiga
Farxiga's label extends its heart-related indication to people with only cardiovascular risk factors, not just diagnosed disease, and reports lower hypoglycemia and volume depletion rates than Jardiance. It does specify an eGFR floor of 45 mL/min/1.73m2 for glycemic benefit and is contraindicated in dialysis, with a slightly higher genital mycotic infection rate than Jardiance's label shows.
Pros
Lower reported rates of hypoglycemia and volume depletion in its label
Lower urinary tract infection rate (up to 4.3%) than Jardiance's (up to 9.3%)
Covers a broader early population for heart-related risk reduction, including those with only cardiovascular risk factors
Cons
Not recommended for glycemic control at eGFR below 45 mL/min/1.73m2
Contraindicated in severe renal impairment or dialysis
Slightly higher genital mycotic infection rate (up to 6.9%) than Jardiance's (up to 5.4%)
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.